Baxter and the International Society of Nephrology (ISN) announced a partnership to advance chronic kidney disease (CKD) awareness and help improve access to therapy, particularly in low- and middle-income countries (LMIC) where the disease prevalence is growing the fastest. The collaboration will support greater disease and therapy research and education, as well as work to help establish better care models that support high standards of care at a lower cost in LMIC.
“ISN and Baxter’s collaboration aims to address the urgent and growing challenge kidney disease is causing healthcare systems in providing quality care to patients globally,” said David Harris, M.D., ISN President, University of Sydney, Australia. “Our organization is dedicated to connecting communities to collaborate on supporting greater access to care models that focus on how to improve prevention, diagnosis and treatment of kidney disease.”
Chronic kidney disease affects 10 percent of the global population. Additionally, it is estimated there are as many as four million people with end-stage renal disease (ESRD) globally, which is the last stage of the disease progression and requires dialysis or a kidney transplant to stay alive. It’s further estimated that millions more go undiagnosed and untreated globally.
“It is Baxter’s goal to make renal care available to people in need, while driving better outcomes through new standards,” said Laura Angelini, general manager, Baxter’s Renal Care business. “Our partnership with ISN moves us closer to this goal by combining Baxter’s clinical and innovation expertise with ISN’s educational and research expertise in a truly transformative approach to increasing access to care worldwide.”